Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Decreases By 14.1%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) was the recipient of a significant decline in short interest in the month of January. As of January 30th, there was short interest totaling 7,870,182 shares, a decline of 14.1% from the January 15th total of 9,166,736 shares. Approximately 17.9% of the shares of the company are short sold. Based on an average daily trading volume, of 997,280 shares, the days-to-cover ratio is currently 7.9 days. Based on an average daily trading volume, of 997,280 shares, the days-to-cover ratio is currently 7.9 days. Approximately 17.9% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ELVN shares. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Trading Up 1.5%

Shares of NASDAQ ELVN traded up $0.40 during midday trading on Wednesday, hitting $26.53. 51,358 shares of the company’s stock were exchanged, compared to its average volume of 1,263,928. The business’s fifty day moving average price is $22.39 and its two-hundred day moving average price is $21.03. The company has a market cap of $1.57 billion, a price-to-earnings ratio of -14.42 and a beta of 0.34. Enliven Therapeutics has a 12-month low of $13.30 and a 12-month high of $30.22.

Insider Activity

In other news, insider Joseph P. Lyssikatos sold 91,198 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the completion of the transaction, the insider owned 765,188 shares in the company, valued at approximately $20,828,417.36. This represents a 10.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anish Patel sold 48,300 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the transaction, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at $6,018,157.89. The trade was a 18.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 232,613 shares of company stock valued at $6,113,287 in the last 90 days. Insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after buying an additional 913 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares during the last quarter. Swiss National Bank lifted its position in Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after buying an additional 1,100 shares during the last quarter. Finally, Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.